Piramal Enterprises acquires five OTC brands for Rs 92 crore
New Delhi: Piramal Enterprises Ltd's (PEL) Consumer Products Division today announced acquisition of five brands from Organon India Pvt Ltd and MSD BV for Rs 92 crore to beef up its offerings in the over-the-counter (OTC) healthcare segment."The acquisition includes mainly the brands Naturolax, Lactobacil and Farizym, which PEL intends to continue in the Gastro-Intestinal (GI) segment through...
Login or Register to read the full article
New Delhi: Piramal Enterprises Ltd's (PEL) Consumer Products Division today announced acquisition of five brands from Organon India Pvt Ltd and MSD BV for Rs 92 crore to beef up its offerings in the over-the-counter (OTC) healthcare segment.
"The acquisition includes mainly the brands Naturolax, Lactobacil and Farizym, which PEL intends to continue in the Gastro-Intestinal (GI) segment through the over-the-counter (OTC) route. The brands hold a rich legacy in India and have a high consumer pull," Piramal Enterprises Ltd said in a BSE filing.
The acquisition of five trademark rights is for India.
"In line with our strategy, we aim to be a top 3 player in the OTC market by 2020 and the addition of this portfolio of brands will help us move swiftly towards that objective," Piramal Enterprises executive director Nandini Piramal said.
Other brands in Piramal's portfolio include Saridon, Ipill, Lacto Calamine, Tetmosol and Caladryl.
Recently the company acquired babycare brand Little's.
Piramal Enterprises COO - Consumer Products Division Kedar Rajadnye added: "We expect these brands to leverage the strong sales and distribution capability that we have built over the years and help us improve our profitability margins as there will be higher fixed cost absorption."
The company said the Indian OTC market is approximately Rs 15,000 crore in size growing at 13-14 per cent.
"The acquisition includes mainly the brands Naturolax, Lactobacil and Farizym, which PEL intends to continue in the Gastro-Intestinal (GI) segment through the over-the-counter (OTC) route. The brands hold a rich legacy in India and have a high consumer pull," Piramal Enterprises Ltd said in a BSE filing.
The acquisition of five trademark rights is for India.
"In line with our strategy, we aim to be a top 3 player in the OTC market by 2020 and the addition of this portfolio of brands will help us move swiftly towards that objective," Piramal Enterprises executive director Nandini Piramal said.
Other brands in Piramal's portfolio include Saridon, Ipill, Lacto Calamine, Tetmosol and Caladryl.
Recently the company acquired babycare brand Little's.
Piramal Enterprises COO - Consumer Products Division Kedar Rajadnye added: "We expect these brands to leverage the strong sales and distribution capability that we have built over the years and help us improve our profitability margins as there will be higher fixed cost absorption."
The company said the Indian OTC market is approximately Rs 15,000 crore in size growing at 13-14 per cent.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd